T-cell therapy formulation
Ex-vivo prepared T-cells are harvested from cell culture conditions and formulated in medium suitable for infusion. The formulation is made by labeling the cells with one or more agents which have reactivity for T-cell surface moieties capable of delivery activation signals upon cross-linking and mixing the labeled cells with biodegradable nanospheres or microspheres coated with a material capable of cross-linking the agents attached to the T-cell surface moieties. Alternatively, the formulation may be made by mixing a population of T-cells with biodegradable nanospheres or microspheres coated with a first material and one or more second materials. The first material binds the second material and the second material has reactivity for surface moieties on the T-cells and the interaction of the second materials with the T-cells causes the activation of the T-cells. In either method, the mixture of T-cells and biodegradable spheres are suspended in a medium suitable for infusion, and the mixture is packaged in a container.
1. A composition comprising a treatment effective amount of cells, of which a portion are T-cells, whereby said T-cells are contacted with one or more first agents that ligate a cell surface moiety on at least a portion of the T-cells, and whereby the first agents are cross-linked by a second agent attached to a biodegradable support to activate the T-cells, and whereby said activated T-cells and biodegradable supports are suspended in a medium suitable for parenteral infusion in an activated state at a concentration of at least 10 7 cells per ml of the medium and packaged in a suitable container for administration of said composition to a patient.
2. The composition of claim 1 whereby the container is collapsible comprising opposing walls of flexible material and a flexible tube protruding from the container.
3. The composition of claim 1 whereby the container is a syringe.